Genelux Corp.
Key Metrics
Market Snapshot
About
Genelux Corp. is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for difficult-to-treat solid tumors. The company's lead product candidate Olvi-Vec is an attenuated vaccinia virus designed to selectively infect and destroy cancer cells while stimulating an anti-tumor immune response. Genelux is advancing multiple clinical programs evaluating Olvi-Vec as monotherapy and in combination with other cancer treatments for various tumor types. The company employs proprietary platform technology to engineer viruses with tumor-selective replication capabilities.